What makes a good potential target for drug discovery?
Listen in as Dr Elizabeth Glennon, of King's College London, discusses how the disruption of axonal transports early on within Alzheimer's Disease provides excellent targets for drug discovery.
How disruption of axonal transport contributes to the development of Alzheimer's disease
Mechanisms of axonal transport of the Alzheimer's amyloid precursor protein, and how these are altered in the disease
Meet our presenter
Elizabeth (Lizzie) Glennon studied her degree in biochemistry at the University of York (UK), followed by a PhD at the Univeristy of Leeds (UK), where she studied molecular mechanisms of neurodegeneration in Alzheimer's disease. Lizzie subsequently moved to King's College London, where she worked as a post doc investigating how a break down in axonal transport may contribute to development of Alzheimers disease.
Lizzie is now an Alzheimer's Research UK fellow at the Institute of Psychiatry, Psychology and Neuroscience at King's College London, where she is investigating how genes linked to Alzheimer's disease could affect the subcellular trafficking of the AD hallmark protein tau.